Neurocrine Biosciences (NBIX) Non Operating Income (2010 - 2026)

Neurocrine Biosciences' Non Operating Income history runs 17 years deep, the most recent figure standing at $53.4 million for Q1 2026.

• Quarterly Non Operating Income rose 700.0% year-over-year to $53.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.6 million (up 619.58% YoY) and the FY2025 annual result came in at $86.3 million, up 202.13% from the prior year.
• Non Operating Income was $53.4 million for Q1 2026 at Neurocrine Biosciences, up from $28.5 million in the prior quarter.
• Across five years, Non Operating Income topped out at $53.4 million in Q1 2026 and bottomed at -$78.0 million in Q2 2022.
• A 5-year average of $6.0 million and a median of $13.9 million in 2025 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income plunged 1371.7% — and 2025, when it jumped 712.31%.
• Neurocrine Biosciences' Non Operating Income stood at $14.5 million in 2022, then surged by 230.34% to $47.9 million in 2023, then slumped by 56.99% to $20.6 million in 2024, then surged by 38.35% to $28.5 million in 2025, then soared by 87.37% to $53.4 million in 2026.
• Business Quant data shows NBIX's Non Operating Income at $53.4 million in Q1 2026, $28.5 million in Q4 2025, and $52.8 million in Q3 2025.